{"ticker": {"uuid": "329d01ac-d480-45f4-9582-8ccc5db69754", "symbol": "ZBIO", "name": "Zenas BioPharma, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "New Zenas hires receive stock awards vesting through 2030", "summary": "Zenas BioPharma (Nasdaq: ZBIO) announced inducement equity awards for new employees, comprising 35,750 non-qualified stock options and 79,050 Restricted Stock Units (RSUs) under its 2026 Inducement Plan. The stock options vest over four years with a 10-year term, an exercise pric", "url": "https://www.stocktitan.net/news/ZBIO/zenas-bio-pharma-announces-inducement-grants-under-nasdaq-listing-wf5axun2zxi4.html", "source_name": "Stock Titan", "published_at": "2026-07-18T01:41:06", "published_display": "18 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees", "summary": "Zenas BioPharma granted stock options and restricted stock units (RSUs) to new employees as an inducement to employment, aligning with Nasdaq rules and aiming to attract and retain top talent. These grants, including options for 35,750 shares and 79,050 RSUs, vest over four years", "url": "https://www.quiverquant.com/news/Zenas+BioPharma+Grants+Inducement+Stock+Options+and+RSUs+to+New+Employees", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T20:41:06", "published_display": "17 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Zenas BioPharma announced inducement grants of non-qualified stock options and restricted stock units to newly hired employees on July 15, 2026. These grants, totaling 35,750 shares of common stock options and 79,050 restricted stock units, were made in accordance with Nasdaq Lis", "url": "https://www.globenewswire.com/news-release/2026/07/17/3329284/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-17T20:41:06", "published_display": "17 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says", "summary": "Wedbush reiterated its Outperform rating on Zenas BioPharma despite a bear case suggesting overvaluation of its lead asset, obexelimab. The firm believes the bear case overlooks obexelimab's significant commercial potential, especially in a market where other treatments have face", "url": "https://www.moomoo.com/news/post/73145319/zenas-biopharma-bear-case-overlooks-obexelimab-s-commercial-potential-wedbush?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-17T12:41:06", "published_display": "17 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise (NASDAQ:ZBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxObkk4Q2NuOS1QT1A1dlZQZ2hIc0lEVWJDUktRNlJEc3FnSk9qS2pBNDJZU0ZfdkhKZkllelVOQ0kxeEJ1Y2NMVlFGNlN2M2h1UmJPUEp5d0pZUUZOMFJ2Um5rYlBFYlRQMWdKYnlKVEdYa1JzUHd6UmwxTlFMV0luUWRDeVNHSUJVWUZ6SzgwTkRJOXdabnNMcEVhYkhWYjVpbVBwcERR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T12:47:00+00:00", "published_display": "14 Jul 2026 12:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma shows promising Phase 3 results for autoimmune drug obexelimab, boosting growth outlook.", "summary": "Zenas BioPharma's obexelimab shows promising Phase 3 results, reducing disease flare-ups by 56% in IgG4-related disease. The company is well-funded with $718.5 million in cash, supporting a product launch and expansion into lupus and multiple sclerosis. Despite a high valuation, ", "url": "https://pluang.com/en/news-feed/zenas-biopharma-obexelimab-bangun-franchise-autoimun", "source_name": "Pluang", "published_at": "2026-07-14T13:10:07", "published_display": "14 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPUmRNanFhN3JwaFR1V1RxU2VQcEJFWFBZZ1M1cnBYSmNia0I5M1VkS19NNGlqMEFqZ1phODFSd0VIQmtlbkhMNGRNLS1KMnpZT19tVTJiUXNsa183clB2MDVIZ1o2dGxVU0NPY1RNaHM2dWJ2a2NSemFaOFNoUm1adjRremRoWUxXNlkxelh3dHpXa3NE?oc=5", "source_name": "Market source", "published_at": "2026-07-10T13:58:53+00:00", "published_display": "10 Jul 2026 13:58", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO) Joins Russell Growth Indexes But Does The Valuation Still Look Pricey", "summary": "Zenas BioPharma (ZBIO) has been reclassified into several Russell growth indexes after significant share price momentum. Despite this, the article questions its current valuation, noting its price-to-book ratio of 5.2x is significantly higher than peers and the industry average, ", "url": "https://www.sahmcapital.com/news/content/zenas-biopharma-zbio-joins-russell-growth-indexes-but-does-the-valuation-still-look-pricey-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-08T11:39:23", "published_display": "08 Jul 2026 11:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Zenas BioPharma (ZBIO) Could Change Following Its Shift Into Russell Growth Indices", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Zenas BioPharma Inc. (ZBIO)", "summary": "This article analyzes the historical performance of Zenas BioPharma Inc. (ZBIO) stock, demonstrating potential returns on $1,000 and $10,000 investments over different periods. It also provides a detailed overview of Zenas BioPharma, a clinical-stage biopharmaceutical company foc", "url": "https://www.stocktitan.net/tools/stock-return-calculator/ZBIO", "source_name": "Stock Titan", "published_at": "2026-07-06T12:12:36", "published_display": "06 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZBIO - Zenas Biopharma Inc Earnings", "summary": "This article provides a detailed financial overview of Zenas Biopharma Inc. (ZBIO), including its market cap, income, sales, key financial ratios, stock performance metrics, and analyst recommendations. It highlights the company's recent stock close, percentage change, and future", "url": "https://finviz.com/stock?t=ZBIO&p=d&ty=ea&b=2", "source_name": "Finviz", "published_at": "2026-07-02T21:39:45", "published_display": "02 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Class Action Lawsuit Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Represents Shareholders", "summary": "A securities class action lawsuit has been filed against Zenas BioPharma, Inc. (NASDAQ:ZBIO) on behalf of investors who purchased shares related to its September 2024 IPO. The lawsuit alleges that Zenas BioPharma misrepresented the amount of time it could fund operations with exi", "url": "https://www.natlawreview.com/press-releases/securities-class-action-lawsuit-filed-against-zenas-biopharma-inc-zbio-levi", "source_name": "The National Law Review", "published_at": "2026-07-01T21:09:14", "published_display": "01 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is urging shareholders who purchased Zenas BioPharma (NASDAQ:ZBIO) securities before September 13, 2024, and still hold them, to inquire about a potential securities investigation. The firm is investigating whether Zenas BioPharma and its office", "url": "https://www.natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-zenas-biopharma-inc-zbio-0", "source_name": "The National Law Review", "published_at": "2026-06-30T12:41:35", "published_display": "30 Jun 2026 12:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor Alert: Deadline Approaching to Join Zenas BioPharma, Inc. (ZBIO) Class Action - Contact Levi & Korsinsky", "summary": "Levi & Korsinsky, LLP announced a class action lawsuit against Zenas BioPharma, Inc. (ZBIO) on behalf of investors who purchased securities following its September 2024 IPO. The lawsuit alleges that Zenas BioPharma misrepresented the duration its existing cash and IPO proceeds co", "url": "https://www.natlawreview.com/press-releases/investor-alert-deadline-approaching-join-zenas-biopharma-inc-zbio-class", "source_name": "The National Law Review", "published_at": "2026-06-29T22:11:06", "published_display": "29 Jun 2026 22:11", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 2500 Growth Benchmark", "summary": "Zenas BioPharma, Inc. (NasdaqGS: ZBIO) has been added to the Russell 2500 Growth Benchmark. This news highlights several recent changes for the company within various Russell indices, including additions to Russell 2000 Growth and Russell Microcap Growth, while being dropped from", "url": "https://www.marketscreener.com/news/zenas-biopharma-inc-nasdaqgs-zbio-added-to-russell-2500-growth-benchmark-ce7f5fdfdd8bf020", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:06:00", "published_display": "29 Jun 2026 16:06", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 3000E Growth Benchmark", "summary": "Zenas BioPharma, Inc. (NasdaqGS: ZBIO) has been added to the Russell 3000E Growth Benchmark, as announced on June 29, 2026. This inclusion reflects recent adjustments to various Russell indices, with Zenas BioPharma also being added to the Russell 2500 Growth and Russell 2000 Gro", "url": "https://www.marketscreener.com/news/zenas-biopharma-inc-nasdaqgs-zbio-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8cf122", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:08:00", "published_display": "29 Jun 2026 05:08", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Zenas BioPharma (ZBIO) Shifting Into Russell Growth Indices Recast Its Core Investment Story?", "summary": "Zenas BioPharma (ZBIO) has transitioned from value to growth classifications in several Russell indices, including the Russell 2000 Growth, which could amplify trading around news due to increased exposure to style and index funds. While this shift primarily affects ownership rat", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/does-zenas-biopharma-zbio-shifting-into-russell-growth-indic", "source_name": "Simply Wall Street", "published_at": "2026-06-29T01:10:30", "published_display": "29 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Zenas BioPharma, Inc. (ZBIO) on behalf of investors who purchased securities prior to September 13, 2024, and still hold them. The investigation seeks to determine if the company and its officers engaged", "url": "https://natlawreview.com/press-releases/zenas-biopharma-inc-zbio-investigation-bronstein-gewirtz-grossman-llc", "source_name": "The National Law Review", "published_at": "2026-06-28T16:09:06", "published_display": "28 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Join Class Action to Recover Losses from Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky Before June 16, 2025", "summary": "Levi & Korsinsky, LLP is inviting investors who suffered losses in Zenas BioPharma, Inc. (ZBIO) to join a class action lawsuit. The lawsuit alleges that Zenas BioPharma made false and misleading statements regarding its ability to fund operations following its September 2024 IPO.", "url": "https://natlawreview.com/press-releases/join-class-action-recover-losses-zenas-biopharma-inc-zbio-contact-levi", "source_name": "The National Law Review", "published_at": "2026-06-27T19:09:06", "published_display": "27 Jun 2026 19:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Investors", "summary": "Levi & Korsinsky has notified investors of Zenas BioPharma, Inc. (ZBIO) about a securities lawsuit, with a lead plaintiff deadline of June 16, 2025. The lawsuit alleges that Zenas BioPharma made false statements regarding its ability to fund operations relying on existing cash an", "url": "https://natlawreview.com/press-releases/levi-korsinsky-notifies-zenas-biopharma-inc-zbio-investors-lead-plaintiff", "source_name": "The National Law Review", "published_at": "2026-06-27T14:09:41", "published_display": "27 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 24, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZBIO DEADLINE NOTICE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm -", "summary": "Rosen Law Firm is notifying investors of Zenas BioPharma, Inc. (NASDAQ: ZBIO) who purchased securities pursuant to the company's September 2024 IPO that the lead plaintiff deadline for a securities class action is June 16, 2025. The lawsuit alleges that the Registration Statement", "url": "https://www.newsfilecorp.com/release/254745/ZBIO-DEADLINE-NOTICE-ROSEN-A-GLOBALLY-RESPECTED-LAW-FIRM-Encourages-Zenas-BioPharma-Inc.-Investors-with-Losses-in-Excess-of-100K-to-Secure-Counsel-Before-Important-June-16-Deadline-in-Securities-Class-Action-First-Filed-by-the-Firm-ZBIO?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-06-27T06:40:48", "published_display": "27 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Zenas BioPharma, Inc. \u2013 BOATS:ZBIO", "summary": "This article briefly displays the \"Enterprise value to EBITDA forward\" metric for Zenas BioPharma, Inc. (ZBIO) on the TradingView platform. It shows that the market for ZBIO was closed with no trades recorded at the time of viewing. The content primarily focuses on presenting thi", "url": "https://www.tradingview.com/symbols/BOATS-ZBIO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:40:19", "published_display": "25 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Zenas BioPharma, Inc. \u2013 NASDAQ:ZBIO", "summary": "This article provides the enterprise value to revenue forward for Zenas BioPharma, Inc. (NASDAQ: ZBIO) as presented on TradingView. It indicates that the market is closed and no trades have occurred. The information is sourced from various financial data providers like ICE Data S", "url": "https://www.tradingview.com/symbols/NASDAQ-ZBIO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:19", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Zenas BioPharma, Inc. \u2013 BOATS:ZBIO", "summary": "This article provides the \"Price to sales forward\" value for Zenas BioPharma, Inc. (ZBIO) on the Blue Ocean Alternative Trade System. It specifies the period, value, and change, noting that the data is provided by ICE Data Services and FactSet. The data indicates that the market ", "url": "https://www.tradingview.com/symbols/BOATS-ZBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:05", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Zenas BioPharma, Inc. \u2013 BOATS:ZBIO", "summary": "This article provides access to the 'Price to book forward' financial metric for Zenas BioPharma, Inc. (ZBIO) on the TradingView platform. It highlights that the market was closed at the time of viewing, indicating no recent trades for the company. The content is primarily a data", "url": "https://www.tradingview.com/symbols/BOATS-ZBIO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T13:11:18", "published_display": "25 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas Biopharma Inc (ZBIO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Zenas Biopharma Inc (ZBIO), noting its current valuation score of 6.82, which ranks 275 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.22, significantly below its recent high. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zbio/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T09:41:16", "published_display": "24 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.", "summary": "", "url": "https://finance.yahoo.com/m/76fe0e63-7964-3893-b474-6495d6ad0229/zenas-biopharma%27s-ceo.html", "source_name": "Motley Fool", "published_at": "2026-06-21T11:31:01+00:00", "published_display": "21 Jun 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma grants new hires 178,075 equity awards", "summary": "Zenas BioPharma (ZBIO) announced the grant of inducement equity awards totaling 178,075 shares to newly hired employees on June 15, 2026, including 100,000 non-qualified stock options with an exercise price of $18.71 and 78,075 Restricted Stock Units (RSUs). These awards, granted", "url": "https://www.stocktitan.net/news/ZBIO/zenas-bio-pharma-announces-inducement-grants-under-nasdaq-listing-iskqm23fw66m.html", "source_name": "Stock Titan", "published_at": "2026-06-21T11:41:36", "published_display": "21 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas Biopharma Inc (ZBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Zenas Biopharma Inc.'s (ZBIO) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no historical stock split data available. The piece presents current stock perform", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zbio/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T17:39:31", "published_display": "18 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO) director awarded 18,500 options at $18.71", "summary": "Zenas BioPharma (ZBIO) director James P. Boylan was granted 18,500 stock options at an exercise price of $18.71 per share as compensation. These options will vest 100% on June 15, 2027, provided Boylan remains in service, and are set to expire on June 15, 2036. The filing indicat", "url": "https://www.stocktitan.net/sec-filings/ZBIO/form-4-zenas-bio-pharma-inc-insider-trading-activity-286ecfb905c7.html", "source_name": "Stock Titan", "published_at": "2026-06-18T14:40:25", "published_display": "18 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas Biopharma Inc (ZBIO) Institutional Confidence", "summary": "Zenas Biopharma Inc (ZBIO) has an institutional shareholding score of 5.00, placing it 133rd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 63.12%, marking a 20.91% decrease quarter-over-quarter. Bill Nygren | OAKMX is the la", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zbio/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:33", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO) awards 18,500 stock options to director Orloff", "summary": "Zenas BioPharma (ZBIO) has granted its director, John J. Orloff, 18,500 stock options with an exercise price of $18.71 per share, expiring on June 15, 2036. The options will vest 100% on June 15, 2027, contingent on his continued service. This transaction is classified as a grant", "url": "https://www.stocktitan.net/sec-filings/ZBIO/form-4-zenas-bio-pharma-inc-insider-trading-activity-e012a8401900.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:39:32", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO) awards 150,000 stock options to officer", "summary": "Zenas BioPharma, Inc. has granted 150,000 stock options to officer Lisa von Moltke. These options have an exercise price of $18.71 per share and will expire on June 15, 2036. The vesting schedule indicates that 25% of the options will vest on June 15, 2027, with the remaining 75%", "url": "https://www.stocktitan.net/sec-filings/ZBIO/form-4-zenas-bio-pharma-inc-insider-trading-activity-2da3db5284a8.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:39:31", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO) director awarded 500K stock options at $18.71", "summary": "Zenas BioPharma (ZBIO) director Leon O. Moulder Jr. was granted 500,000 stock options with an exercise price of $18.71 per share, expiring on June 15, 2036. The options will vest 25% on June 15, 2027, with the remaining shares vesting monthly over 36 months, subject to continued ", "url": "https://www.stocktitan.net/sec-filings/ZBIO/form-4-zenas-bio-pharma-inc-insider-trading-activity-b2c8a03d6267.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:09:40", "published_display": "18 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$ZBIO stock is up 10% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNMFdyWmVZNjg5SVhWUUI2bkVZaWVLdFBjZV9iekRtOFA3MTBCUk9seklKVzlpLVJudW1ZZmxjQ1FHOUVhRXBEMHlmUDJLT2NlVGhyUGRYOFl6VmNYalBTU1dfOEtBcXFlSmg5V2N4bkN3a01NT1pvdkxmOEoxdU9zUVhKQ0tmU2hWOXE5QlhkNkJaclZIVk5jdXAwQS1wZkhq?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zenas-biopharma-present-h-c-201500057.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T20:15:00+00:00", "published_display": "11 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma's Potential Autoimmune Disease Treatment Meets Primary, Secondary Endpoints in Phase 3 Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zenas-biopharma-apos-potential-autoimmune-084149898.html", "source_name": "MT Newswires", "published_at": "2026-06-03T08:41:49+00:00", "published_display": "03 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zenas-biopharma-announces-data-registrational-230500180.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T23:05:00+00:00", "published_display": "02 Jun 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQbkVHOG85VWkzeUNCa0h0bEE3Rkk1S2ZzQUVyR0NibmlqakxoRW9SWXNwTFlwRW9nVTBvQzhTTGRUNFpqZ0Z4T2NLczdiODc3ZGdIZDVaSWN4UVlITXUzTkItZXNTdFpjYnppZ0syeUJMaHUtUF93cnUzT0RJZEtZamowRVpucU03S0pfSkJXaVZ6Y2h2V1BuVVJLMHZGb05SR0ZlT2tsQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ZBIO Stock Price and Chart \u2014 NASDAQ:ZBIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9zOWdQTDN4SXlrR1RXaFVEVmdwblNybkVpQTZSclJCSVNNa3I4OThrZC1wSHZ5VzlPbUxLSEM0V3FHMEo4eWNrZXFhbmhiUXBQMEZqQTVYU0VMb1Vr?oc=5", "source_name": "TradingView", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wJBVV95cUxNWFFZVDVoMDBJeTh0X01EQjhib1VEUnVQMXloZ0dwY0tONHRSelVZa0VpZnRWc1RRMTJLaGhXVWdBalBBZjhNTnZrSGVqdlV2dzlpZE96ODgtVm9OMEFBdVZ0QXVLUENhZ2dPdVZDbS15Z3hZdElnX2Q4cFFoa1BtR3lvOWNtUjdyMDl6Rko2bzZTMXRLbWdLRHRmX09ySVltWl96Z2xXcmVQQmUxcjg5WTV2OFNVM29WVEh5MUFITDE1TkE5elp5TE9NamQwdjVSQ2dZbHVja0YybmNSdWtRbjBzSkl3Qm84SVlxZXEyczdLY0pQRW1SU0RPaTFnTGU3NE9DX08xVlgzN3I4MGgxejYyTFhGUktWRnBaV0pUOERoMDNuWE9lSEFKRHdjQS1La3RZbjhIOVYzbUZHSFFzUWJCZ1A2RDVXV1JqbjdhcWc0cUcyMDdyRWxkSktsUUU?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma Announces Proposed Concurrent Public", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxNd1I2djdDbWxnOHJEVjVZbkpDc2VUcDdoYkJheXZKdjY0VjhYTWpsNTBUeENmSFdZMzJsRDhleU9YY3JBNTlRNU1HaVY0QVFjQ2c4M19jUy01OEpNcGVQZjNUeTA5eGpwY2NaNmJ4MF8teGViLWw4M1B2TWJ2TzNCWVl1WEJDc2JCQmJmN0hZUzBxYzlPT2JBT1g4S245MExBR0Q3bFctUndzWUQ2MFp0ZWpnSnQxTWM1VVBpVk5OZEhleGR2SE9KT0tHRlFDdVVDUzFoV0psTkFhZFFqMHdtdXBBZmlDYWxGOXh3MnV1Yy1WWkVJY1haakQxZ0VhUmtYSW92am8xQzhBbHFlTklFakI5OEN0Tms?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas seeks fresh cash for planned drug launch, Phase 3 studies", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOdFhZYXlSTGRvU0NMU1NMdFludE5OeTZ1dGI1Rl9KZlI3Zy1Iakdia0w0eUdMNWpNczYzaG9JS1Z0M2NZeEJXdEJZdWxGZEdJdXlKV2Rid014Wmx2NE9SMXZhS0ExSmNvOHU0eVNPLWx0M2Y1dENwZnVPVnlzVDJ2ODRvSjRxT1dIc0xiUzFVLXdjRGV6M05oYV9FWDVNS2VDRE9RRHMwZFRJU3BPa3Y0MEVoMXh1UnJ4Z1I1VGlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "New Zenas hires receive stock awards vesting through 2030", "summary": "Zenas BioPharma (Nasdaq: ZBIO) announced inducement equity awards for new employees, comprising 35,750 non-qualified stock options and 79,050 Restricted Stock Units (RSUs) under its 2026 Inducement Plan. The stock options vest over four years with a 10-year term, an exercise pric", "url": "https://www.stocktitan.net/news/ZBIO/zenas-bio-pharma-announces-inducement-grants-under-nasdaq-listing-wf5axun2zxi4.html", "source_name": "Stock Titan", "published_at": "2026-07-18T01:41:06", "published_display": "18 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees", "summary": "Zenas BioPharma granted stock options and restricted stock units (RSUs) to new employees as an inducement to employment, aligning with Nasdaq rules and aiming to attract and retain top talent. These grants, including options for 35,750 shares and 79,050 RSUs, vest over four years", "url": "https://www.quiverquant.com/news/Zenas+BioPharma+Grants+Inducement+Stock+Options+and+RSUs+to+New+Employees", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T20:41:06", "published_display": "17 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Zenas BioPharma announced inducement grants of non-qualified stock options and restricted stock units to newly hired employees on July 15, 2026. These grants, totaling 35,750 shares of common stock options and 79,050 restricted stock units, were made in accordance with Nasdaq Lis", "url": "https://www.globenewswire.com/news-release/2026/07/17/3329284/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "source_name": "GlobeNewswire", "published_at": "2026-07-17T20:41:06", "published_display": "17 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says", "summary": "Wedbush reiterated its Outperform rating on Zenas BioPharma despite a bear case suggesting overvaluation of its lead asset, obexelimab. The firm believes the bear case overlooks obexelimab's significant commercial potential, especially in a market where other treatments have face", "url": "https://www.moomoo.com/news/post/73145319/zenas-biopharma-bear-case-overlooks-obexelimab-s-commercial-potential-wedbush?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-17T12:41:06", "published_display": "17 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise (NASDAQ:ZBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxObkk4Q2NuOS1QT1A1dlZQZ2hIc0lEVWJDUktRNlJEc3FnSk9qS2pBNDJZU0ZfdkhKZkllelVOQ0kxeEJ1Y2NMVlFGNlN2M2h1UmJPUEp5d0pZUUZOMFJ2Um5rYlBFYlRQMWdKYnlKVEdYa1JzUHd6UmwxTlFMV0luUWRDeVNHSUJVWUZ6SzgwTkRJOXdabnNMcEVhYkhWYjVpbVBwcERR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T12:47:00+00:00", "published_display": "14 Jul 2026 12:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma shows promising Phase 3 results for autoimmune drug obexelimab, boosting growth outlook.", "summary": "Zenas BioPharma's obexelimab shows promising Phase 3 results, reducing disease flare-ups by 56% in IgG4-related disease. The company is well-funded with $718.5 million in cash, supporting a product launch and expansion into lupus and multiple sclerosis. Despite a high valuation, ", "url": "https://pluang.com/en/news-feed/zenas-biopharma-obexelimab-bangun-franchise-autoimun", "source_name": "Pluang", "published_at": "2026-07-14T13:10:07", "published_display": "14 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 92, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPUmRNanFhN3JwaFR1V1RxU2VQcEJFWFBZZ1M1cnBYSmNia0I5M1VkS19NNGlqMEFqZ1phODFSd0VIQmtlbkhMNGRNLS1KMnpZT19tVTJiUXNsa183clB2MDVIZ1o2dGxVU0NPY1RNaHM2dWJ2a2NSemFaOFNoUm1adjRremRoWUxXNlkxelh3dHpXa3NE?oc=5", "source_name": "Market source", "published_at": "2026-07-10T13:58:53+00:00", "published_display": "10 Jul 2026 13:58", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO) Joins Russell Growth Indexes But Does The Valuation Still Look Pricey", "summary": "Zenas BioPharma (ZBIO) has been reclassified into several Russell growth indexes after significant share price momentum. Despite this, the article questions its current valuation, noting its price-to-book ratio of 5.2x is significantly higher than peers and the industry average, ", "url": "https://www.sahmcapital.com/news/content/zenas-biopharma-zbio-joins-russell-growth-indexes-but-does-the-valuation-still-look-pricey-2026-07-08", "source_name": "Sahm", "published_at": "2026-07-08T11:39:23", "published_display": "08 Jul 2026 11:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Zenas BioPharma (ZBIO) Could Change Following Its Shift Into Russell Growth Indices", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Zenas BioPharma Inc. (ZBIO)", "summary": "This article analyzes the historical performance of Zenas BioPharma Inc. (ZBIO) stock, demonstrating potential returns on $1,000 and $10,000 investments over different periods. It also provides a detailed overview of Zenas BioPharma, a clinical-stage biopharmaceutical company foc", "url": "https://www.stocktitan.net/tools/stock-return-calculator/ZBIO", "source_name": "Stock Titan", "published_at": "2026-07-06T12:12:36", "published_display": "06 Jul 2026 12:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZBIO - Zenas Biopharma Inc Earnings", "summary": "This article provides a detailed financial overview of Zenas Biopharma Inc. (ZBIO), including its market cap, income, sales, key financial ratios, stock performance metrics, and analyst recommendations. It highlights the company's recent stock close, percentage change, and future", "url": "https://finviz.com/stock?t=ZBIO&p=d&ty=ea&b=2", "source_name": "Finviz", "published_at": "2026-07-02T21:39:45", "published_display": "02 Jul 2026 21:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Class Action Lawsuit Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Represents Shareholders", "summary": "A securities class action lawsuit has been filed against Zenas BioPharma, Inc. (NASDAQ:ZBIO) on behalf of investors who purchased shares related to its September 2024 IPO. The lawsuit alleges that Zenas BioPharma misrepresented the amount of time it could fund operations with exi", "url": "https://www.natlawreview.com/press-releases/securities-class-action-lawsuit-filed-against-zenas-biopharma-inc-zbio-levi", "source_name": "The National Law Review", "published_at": "2026-07-01T21:09:14", "published_display": "01 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is urging shareholders who purchased Zenas BioPharma (NASDAQ:ZBIO) securities before September 13, 2024, and still hold them, to inquire about a potential securities investigation. The firm is investigating whether Zenas BioPharma and its office", "url": "https://www.natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-encourages-zenas-biopharma-inc-zbio-0", "source_name": "The National Law Review", "published_at": "2026-06-30T12:41:35", "published_display": "30 Jun 2026 12:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor Alert: Deadline Approaching to Join Zenas BioPharma, Inc. (ZBIO) Class Action - Contact Levi & Korsinsky", "summary": "Levi & Korsinsky, LLP announced a class action lawsuit against Zenas BioPharma, Inc. (ZBIO) on behalf of investors who purchased securities following its September 2024 IPO. The lawsuit alleges that Zenas BioPharma misrepresented the duration its existing cash and IPO proceeds co", "url": "https://www.natlawreview.com/press-releases/investor-alert-deadline-approaching-join-zenas-biopharma-inc-zbio-class", "source_name": "The National Law Review", "published_at": "2026-06-29T22:11:06", "published_display": "29 Jun 2026 22:11", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 2500 Growth Benchmark", "summary": "Zenas BioPharma, Inc. (NasdaqGS: ZBIO) has been added to the Russell 2500 Growth Benchmark. This news highlights several recent changes for the company within various Russell indices, including additions to Russell 2000 Growth and Russell Microcap Growth, while being dropped from", "url": "https://www.marketscreener.com/news/zenas-biopharma-inc-nasdaqgs-zbio-added-to-russell-2500-growth-benchmark-ce7f5fdfdd8bf020", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:06:00", "published_display": "29 Jun 2026 16:06", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 3000E Growth Benchmark", "summary": "Zenas BioPharma, Inc. (NasdaqGS: ZBIO) has been added to the Russell 3000E Growth Benchmark, as announced on June 29, 2026. This inclusion reflects recent adjustments to various Russell indices, with Zenas BioPharma also being added to the Russell 2500 Growth and Russell 2000 Gro", "url": "https://www.marketscreener.com/news/zenas-biopharma-inc-nasdaqgs-zbio-added-to-russell-3000e-growth-benchmark-ce7f5fdedf8cf122", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:08:00", "published_display": "29 Jun 2026 05:08", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Zenas BioPharma (ZBIO) Shifting Into Russell Growth Indices Recast Its Core Investment Story?", "summary": "Zenas BioPharma (ZBIO) has transitioned from value to growth classifications in several Russell indices, including the Russell 2000 Growth, which could amplify trading around news due to increased exposure to style and index funds. While this shift primarily affects ownership rat", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/does-zenas-biopharma-zbio-shifting-into-russell-growth-indic", "source_name": "Simply Wall Street", "published_at": "2026-06-29T01:10:30", "published_display": "29 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Zenas BioPharma, Inc. (ZBIO) on behalf of investors who purchased securities prior to September 13, 2024, and still hold them. The investigation seeks to determine if the company and its officers engaged", "url": "https://natlawreview.com/press-releases/zenas-biopharma-inc-zbio-investigation-bronstein-gewirtz-grossman-llc", "source_name": "The National Law Review", "published_at": "2026-06-28T16:09:06", "published_display": "28 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Join Class Action to Recover Losses from Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky Before June 16, 2025", "summary": "Levi & Korsinsky, LLP is inviting investors who suffered losses in Zenas BioPharma, Inc. (ZBIO) to join a class action lawsuit. The lawsuit alleges that Zenas BioPharma made false and misleading statements regarding its ability to fund operations following its September 2024 IPO.", "url": "https://natlawreview.com/press-releases/join-class-action-recover-losses-zenas-biopharma-inc-zbio-contact-levi", "source_name": "The National Law Review", "published_at": "2026-06-27T19:09:06", "published_display": "27 Jun 2026 19:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Investors", "summary": "Levi & Korsinsky has notified investors of Zenas BioPharma, Inc. (ZBIO) about a securities lawsuit, with a lead plaintiff deadline of June 16, 2025. The lawsuit alleges that Zenas BioPharma made false statements regarding its ability to fund operations relying on existing cash an", "url": "https://natlawreview.com/press-releases/levi-korsinsky-notifies-zenas-biopharma-inc-zbio-investors-lead-plaintiff", "source_name": "The National Law Review", "published_at": "2026-06-27T14:09:41", "published_display": "27 Jun 2026 14:09", "sentiment": "negative", "sentiment_pct": 24, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZBIO DEADLINE NOTICE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm -", "summary": "Rosen Law Firm is notifying investors of Zenas BioPharma, Inc. (NASDAQ: ZBIO) who purchased securities pursuant to the company's September 2024 IPO that the lead plaintiff deadline for a securities class action is June 16, 2025. The lawsuit alleges that the Registration Statement", "url": "https://www.newsfilecorp.com/release/254745/ZBIO-DEADLINE-NOTICE-ROSEN-A-GLOBALLY-RESPECTED-LAW-FIRM-Encourages-Zenas-BioPharma-Inc.-Investors-with-Losses-in-Excess-of-100K-to-Secure-Counsel-Before-Important-June-16-Deadline-in-Securities-Class-Action-First-Filed-by-the-Firm-ZBIO?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-06-27T06:40:48", "published_display": "27 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Zenas BioPharma, Inc. \u2013 BOATS:ZBIO", "summary": "This article briefly displays the \"Enterprise value to EBITDA forward\" metric for Zenas BioPharma, Inc. (ZBIO) on the TradingView platform. It shows that the market for ZBIO was closed with no trades recorded at the time of viewing. The content primarily focuses on presenting thi", "url": "https://www.tradingview.com/symbols/BOATS-ZBIO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T23:40:19", "published_display": "25 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Zenas BioPharma, Inc. \u2013 NASDAQ:ZBIO", "summary": "This article provides the enterprise value to revenue forward for Zenas BioPharma, Inc. (NASDAQ: ZBIO) as presented on TradingView. It indicates that the market is closed and no trades have occurred. The information is sourced from various financial data providers like ICE Data S", "url": "https://www.tradingview.com/symbols/NASDAQ-ZBIO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:19", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Zenas BioPharma, Inc. \u2013 BOATS:ZBIO", "summary": "This article provides the \"Price to sales forward\" value for Zenas BioPharma, Inc. (ZBIO) on the Blue Ocean Alternative Trade System. It specifies the period, value, and change, noting that the data is provided by ICE Data Services and FactSet. The data indicates that the market ", "url": "https://www.tradingview.com/symbols/BOATS-ZBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:05", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Zenas BioPharma, Inc. \u2013 BOATS:ZBIO", "summary": "This article provides access to the 'Price to book forward' financial metric for Zenas BioPharma, Inc. (ZBIO) on the TradingView platform. It highlights that the market was closed at the time of viewing, indicating no recent trades for the company. The content is primarily a data", "url": "https://www.tradingview.com/symbols/BOATS-ZBIO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T13:11:18", "published_display": "25 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas Biopharma Inc (ZBIO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Zenas Biopharma Inc (ZBIO), noting its current valuation score of 6.82, which ranks 275 out of 389 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.22, significantly below its recent high. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zbio/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T09:41:16", "published_display": "24 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.", "summary": "", "url": "https://finance.yahoo.com/m/76fe0e63-7964-3893-b474-6495d6ad0229/zenas-biopharma%27s-ceo.html", "source_name": "Motley Fool", "published_at": "2026-06-21T11:31:01+00:00", "published_display": "21 Jun 2026 11:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma grants new hires 178,075 equity awards", "summary": "Zenas BioPharma (ZBIO) announced the grant of inducement equity awards totaling 178,075 shares to newly hired employees on June 15, 2026, including 100,000 non-qualified stock options with an exercise price of $18.71 and 78,075 Restricted Stock Units (RSUs). These awards, granted", "url": "https://www.stocktitan.net/news/ZBIO/zenas-bio-pharma-announces-inducement-grants-under-nasdaq-listing-iskqm23fw66m.html", "source_name": "Stock Titan", "published_at": "2026-06-21T11:41:36", "published_display": "21 Jun 2026 11:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas Biopharma Inc (ZBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Zenas Biopharma Inc.'s (ZBIO) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no historical stock split data available. The piece presents current stock perform", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zbio/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T17:39:31", "published_display": "18 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO) director awarded 18,500 options at $18.71", "summary": "Zenas BioPharma (ZBIO) director James P. Boylan was granted 18,500 stock options at an exercise price of $18.71 per share as compensation. These options will vest 100% on June 15, 2027, provided Boylan remains in service, and are set to expire on June 15, 2036. The filing indicat", "url": "https://www.stocktitan.net/sec-filings/ZBIO/form-4-zenas-bio-pharma-inc-insider-trading-activity-286ecfb905c7.html", "source_name": "Stock Titan", "published_at": "2026-06-18T14:40:25", "published_display": "18 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas Biopharma Inc (ZBIO) Institutional Confidence", "summary": "Zenas Biopharma Inc (ZBIO) has an institutional shareholding score of 5.00, placing it 133rd in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 63.12%, marking a 20.91% decrease quarter-over-quarter. Bill Nygren | OAKMX is the la", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-zbio/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:33", "published_display": "18 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO) awards 18,500 stock options to director Orloff", "summary": "Zenas BioPharma (ZBIO) has granted its director, John J. Orloff, 18,500 stock options with an exercise price of $18.71 per share, expiring on June 15, 2036. The options will vest 100% on June 15, 2027, contingent on his continued service. This transaction is classified as a grant", "url": "https://www.stocktitan.net/sec-filings/ZBIO/form-4-zenas-bio-pharma-inc-insider-trading-activity-e012a8401900.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:39:32", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO) awards 150,000 stock options to officer", "summary": "Zenas BioPharma, Inc. has granted 150,000 stock options to officer Lisa von Moltke. These options have an exercise price of $18.71 per share and will expire on June 15, 2036. The vesting schedule indicates that 25% of the options will vest on June 15, 2027, with the remaining 75%", "url": "https://www.stocktitan.net/sec-filings/ZBIO/form-4-zenas-bio-pharma-inc-insider-trading-activity-2da3db5284a8.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:39:31", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma (ZBIO) director awarded 500K stock options at $18.71", "summary": "Zenas BioPharma (ZBIO) director Leon O. Moulder Jr. was granted 500,000 stock options with an exercise price of $18.71 per share, expiring on June 15, 2036. The options will vest 25% on June 15, 2027, with the remaining shares vesting monthly over 36 months, subject to continued ", "url": "https://www.stocktitan.net/sec-filings/ZBIO/form-4-zenas-bio-pharma-inc-insider-trading-activity-b2c8a03d6267.html", "source_name": "Stock Titan", "published_at": "2026-06-18T02:09:40", "published_display": "18 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$ZBIO stock is up 10% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNMFdyWmVZNjg5SVhWUUI2bkVZaWVLdFBjZV9iekRtOFA3MTBCUk9seklKVzlpLVJudW1ZZmxjQ1FHOUVhRXBEMHlmUDJLT2NlVGhyUGRYOFl6VmNYalBTU1dfOEtBcXFlSmg5V2N4bkN3a01NT1pvdkxmOEoxdU9zUVhKQ0tmU2hWOXE5QlhkNkJaclZIVk5jdXAwQS1wZkhq?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zenas-biopharma-present-h-c-201500057.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T20:15:00+00:00", "published_display": "11 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma's Potential Autoimmune Disease Treatment Meets Primary, Secondary Endpoints in Phase 3 Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zenas-biopharma-apos-potential-autoimmune-084149898.html", "source_name": "MT Newswires", "published_at": "2026-06-03T08:41:49+00:00", "published_display": "03 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/zenas-biopharma-announces-data-registrational-230500180.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T23:05:00+00:00", "published_display": "02 Jun 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Zenas BioPharma (ZBIO) Valuation After Strong 1-Year Return And Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQbkVHOG85VWkzeUNCa0h0bEE3Rkk1S2ZzQUVyR0NibmlqakxoRW9SWXNwTFlwRW9nVTBvQzhTTGRUNFpqZ0Z4T2NLczdiODc3ZGdIZDVaSWN4UVlITXUzTkItZXNTdFpjYnppZ0syeUJMaHUtUF93cnUzT0RJZEtZamowRVpucU03S0pfSkJXaVZ6Y2h2V1BuVVJLMHZGb05SR0ZlT2tsQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ZBIO Stock Price and Chart \u2014 NASDAQ:ZBIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9zOWdQTDN4SXlrR1RXaFVEVmdwblNybkVpQTZSclJCSVNNa3I4OThrZC1wSHZ5VzlPbUxLSEM0V3FHMEo4eWNrZXFhbmhiUXBQMEZqQTVYU0VMb1Vr?oc=5", "source_name": "TradingView", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wJBVV95cUxNWFFZVDVoMDBJeTh0X01EQjhib1VEUnVQMXloZ0dwY0tONHRSelVZa0VpZnRWc1RRMTJLaGhXVWdBalBBZjhNTnZrSGVqdlV2dzlpZE96ODgtVm9OMEFBdVZ0QXVLUENhZ2dPdVZDbS15Z3hZdElnX2Q4cFFoa1BtR3lvOWNtUjdyMDl6Rko2bzZTMXRLbWdLRHRmX09ySVltWl96Z2xXcmVQQmUxcjg5WTV2OFNVM29WVEh5MUFITDE1TkE5elp5TE9NamQwdjVSQ2dZbHVja0YybmNSdWtRbjBzSkl3Qm84SVlxZXEyczdLY0pQRW1SU0RPaTFnTGU3NE9DX08xVlgzN3I4MGgxejYyTFhGUktWRnBaV0pUOERoMDNuWE9lSEFKRHdjQS1La3RZbjhIOVYzbUZHSFFzUWJCZ1A2RDVXV1JqbjdhcWc0cUcyMDdyRWxkSktsUUU?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas BioPharma Announces Proposed Concurrent Public", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxNd1I2djdDbWxnOHJEVjVZbkpDc2VUcDdoYkJheXZKdjY0VjhYTWpsNTBUeENmSFdZMzJsRDhleU9YY3JBNTlRNU1HaVY0QVFjQ2c4M19jUy01OEpNcGVQZjNUeTA5eGpwY2NaNmJ4MF8teGViLWw4M1B2TWJ2TzNCWVl1WEJDc2JCQmJmN0hZUzBxYzlPT2JBT1g4S245MExBR0Q3bFctUndzWUQ2MFp0ZWpnSnQxTWM1VVBpVk5OZEhleGR2SE9KT0tHRlFDdVVDUzFoV0psTkFhZFFqMHdtdXBBZmlDYWxGOXh3MnV1Yy1WWkVJY1haakQxZ0VhUmtYSW92am8xQzhBbHFlTklFakI5OEN0Tms?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zenas seeks fresh cash for planned drug launch, Phase 3 studies", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOdFhZYXlSTGRvU0NMU1NMdFludE5OeTZ1dGI1Rl9KZlI3Zy1Iakdia0w0eUdMNWpNczYzaG9JS1Z0M2NZeEJXdEJZdWxGZEdJdXlKV2Rid014Wmx2NE9SMXZhS0ExSmNvOHU0eVNPLWx0M2Y1dENwZnVPVnlzVDJ2ODRvSjRxT1dIc0xiUzFVLXdjRGV6M05oYV9FWDVNS2VDRE9RRHMwZFRJU3BPa3Y0MEVoMXh1UnJ4Z1I1VGlR?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 71, "sentiment_summary": {"positive": 18, "negative": 11, "neutral": 42, "score": 50, "total": 71, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 22.7, "count": 40}, {"event": "earnings", "label": "Earnings", "weight": 10.6, "count": 20}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.85, "count": 7}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 11}, "market_context": {"has_market_context": true, "latest_close": 28.74, "latest_week": "2026-07-10", "one_week_move": 5.5, "four_week_move": 45.2, "twelve_week_move": 31.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.082525, "market_dynamics_buy_signal": false, "relative_strength": 3.736308, "fair_value_gap": 58.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 49.5005, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.5% over one week, +45.2% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 7}, {"label": "The National Law Review", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "Quiver Quantitative", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "TradingKey", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 63}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 40}, {"label": "Earnings", "count": 20}, {"label": "Regulatory and legal", "count": 7}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "63", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.5% over one week, +45.2% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "New Zenas hires receive stock awards vesting through 2030"}], "updated_at": "2026-07-18T04:15:32.931373+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}